Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E149.58 EPS (ttm)0.19 Insider Own1.00% Shs Outstand290.39M Perf Week4.28%
Market Cap8.21B Forward P/E42.64 EPS next Y0.66 Insider Trans-32.92% Shs Float276.47M Perf Month7.21%
Income58.20M PEG3.25 EPS next Q0.08 Inst Own81.00% Short Float5.63% Perf Quarter17.69%
Sales319.70M P/S25.68 EPS this Y63.70% Inst Trans-1.09% Short Ratio3.76 Perf Half Y38.04%
Book/sh0.51 P/B55.43 EPS next Y147.39% ROA10.40% Target Price30.43 Perf Year99.65%
Cash/sh1.20 P/C23.51 EPS next 5Y46.00% ROE59.70% 52W Range10.04 - 29.50 Perf YTD89.60%
Dividend- P/FCF55.96 EPS past 5Y-19.90% ROI-15.10% 52W High-4.51% Beta1.96
Dividend %- Quick Ratio4.10 Sales past 5Y-7.90% Gross Margin96.70% 52W Low180.58% ATR0.91
Employees287 Current Ratio4.10 Sales Q/Q172.70% Oper. Margin22.90% RSI (14)56.81 Volatility2.52% 3.62%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin18.20% Rel Volume0.41 Prev Close28.27
ShortableYes LT Debt/Eq0.00 EarningsAug 02 AMC Payout0.00% Avg Volume4.14M Price28.17
Recom2.10 SMA202.52% SMA503.97% SMA20027.81% Volume609,957 Change-0.35%
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Sep-20-17 06:32AM  Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool
05:37AM  [$$] Exelixis CEO, CFO Sell $11 Million in Stock Barrons.com
Sep-19-17 04:05PM  Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25 Business Wire
Sep-15-17 01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
06:04AM  Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis? Motley Fool
Sep-14-17 08:21PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : September 15, 2017 Capital Cube
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
Sep-13-17 09:44AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017 Capital Cube
Sep-11-17 10:10AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-10-17 07:17AM  Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors Motley Fool
Sep-09-17 06:09PM  Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 Business Wire
Sep-08-17 03:22PM  Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer Investor's Business Daily
10:34AM  2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August Motley Fool
10:23AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
06:08AM  Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock Motley Fool
Sep-07-17 08:16AM  Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy Business Wire -8.91%
Sep-06-17 05:23PM  Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress Business Wire
Sep-02-17 08:09AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-01-17 08:47AM  Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-31-17 08:00AM  Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation ACCESSWIRE
Aug-29-17 04:05PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 Business Wire
01:59PM  Analyst Recommendations for Regeneron Pharmaceuticals in August Market Realist
Aug-27-17 03:04PM  Can Buying Exelixis Stock Still Make You Rich? Motley Fool
Aug-24-17 10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-18-17 07:40AM  Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer ACCESSWIRE
Aug-17-17 05:59PM  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx Zacks
12:31PM  Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-16-17 09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc. ACCESSWIRE
07:00AM  Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer Business Wire
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-11-17 08:02AM  IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-09-17 11:18AM  Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts Motley Fool
Aug-04-17 04:35PM  Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass Zacks
02:50PM  Exelixis, Inc. Grows Revenue, Eyes Treating More Patients Motley Fool
10:12AM  Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
04:21PM  Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales Zacks
03:41PM  3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance Motley Fool
02:41PM  The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom Benzinga
11:33AM  Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch SmarterAnalyst
01:07AM  Exelixis tops Street 2Q forecasts Associated Press
Aug-02-17 04:05PM  Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:20PM  Investor Network: Exelixis, Inc. to Host Earnings Call ACCESSWIRE
10:24AM  Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Aug-01-17 10:46AM  Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2 Zacks
08:00AM  Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress Business Wire
Jul-31-17 01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
10:44AM  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise Zacks
Jul-28-17 02:33PM  Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line Zacks
Jul-27-17 12:04PM  Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View Zacks
11:27AM  GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance Zacks
08:00AM  Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up Zacks
Jul-25-17 04:25PM  Three biotech companies to watch ahead of earnings MarketWatch
Jul-24-17 10:44AM  What's in the Cards for Exelixis (EXEL) in Q2 Earnings? Zacks
Jul-21-17 02:42PM  2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't Motley Fool
12:57PM  William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL) SmarterAnalyst
Jul-20-17 06:19PM  Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab Zacks
07:00AM  Exelixis Announces Settlement of Dispute with Genentech Regarding Companies Collaboration Agreement for Cobimetinib Business Wire
Jul-19-17 10:16AM  Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt Zacks
08:15AM  Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session Zacks
Jul-17-17 06:49PM  Cramer's lightning round: This business is better than people think CNBC
04:05PM  Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 Business Wire
03:11PM  Arena Announces Secondary Stock Worth $150M (revised) Zacks
Jul-13-17 06:11PM  Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017? Zacks
06:03PM  BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug Zacks
08:50AM  Why Exelixis (EXEL) Could Be an Impressive Growth Stock Zacks
Jul-12-17 10:13AM  Arena Announces Secondary Stock Offering of 150M Shares Zacks
Jul-11-17 05:08PM  Five Scorching Hot Stocks Screaming Higher Zacks
04:44PM  Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx Zacks
Jul-10-17 09:40AM  Biotech Movers: Exelixis, Omeros, Inovio TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc. Accesswire
08:00AM  Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
Jul-07-17 09:05AM  This Biotech Finds Its Stride With Kidney Cancer Treatment Investor's Business Daily
08:24AM  The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32% Motley Fool
Jul-05-17 04:12PM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
11:44AM  3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates Motley Fool
09:54AM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners Zacks
Jul-03-17 02:43PM  Top Analyst Reports for Disney, Charter Communications & Monsanto Zacks
11:43AM  Best Stocks For The Second Half of 2017 Zacks
Jun-29-17 08:00AM  Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness Business Wire
Jun-27-17 10:28AM  Top Ranked Momentum Stocks to Buy for June 27th Zacks -5.26%
08:00AM  Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics Accesswire
Jun-26-17 04:20PM  Biotech Rally Gets Second Wind As This Small Cap Nears Breaks Out Investor's Business Daily
04:17PM  Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone Investor's Business Daily
11:32AM  This Drugmaker Flirts With Breakout As Some Biotechs Rally Investor's Business Daily
06:00AM  The Reason for the Big Rise in Biotech Stocks Investopedia
Jun-25-17 09:42AM  These 3 Stocks Are Up Over 500% in the Last 3 Years Motley Fool
Jun-24-17 06:42AM  Better Buy: Exelixis, Inc. vs. Novartis AG Motley Fool
Jun-23-17 12:06PM  Roundtable: 1 Stock I Brag About Owning Motley Fool
Jun-22-17 04:55PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : June 22, 2017 Capital Cube
04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
02:50AM  Biotech Exelixis May Break Out On Cancer Drug Trial Results Investor's Business Daily
Jun-21-17 02:58PM  Two Bullish Biotech Stocks And A Very Bearish Looking Yelp Forbes +7.81%
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM